Table 3.
Association of mannose-binding lectin concentration with number of COPD exacerbations
| Variable |
MBL concentration (ng/mL)
|
|||||
|---|---|---|---|---|---|---|
| ≤100 | >100 | ≤500 | >500 | >50 and ≤1000 | >1000 | |
| Total subjects, n | 20 | 1017 | 251 | 786 | 542 | 490 |
| Frequency of AECOPDs (all subjects), n (%) | ||||||
| 0 | 9 (45%) | 372 (37%) | 95 (38%) | 286 (36%) | 202 (37%) | 176 (36%) |
| 1–2 | 9 (45%) | 425 (42%) | 105 (42%) | 329 (42%) | 223 (41%) | 209 (43%) |
| ≥3 | 2 (10%) | 220 (22%) | 51 (20%) | 171 (22%) | 117 (22%) | 105 (21%) |
| Frequency of AECOPDs (subjects receiving azithromycin), n (%) | 8 | 512 | 106 | 414 | 258 | 261 |
| 0 | 4 (50%) | 220 (43%) | 48 (45%) | 176 (43%) | 116 (45%) | 107 (41%) |
| 1–2 | 3 (38%) | 193 (38%) | 40 (38%) | 156 (38%) | 92 (36%) | 104 (40%) |
| ≥3 | 1 (13%) | 99 (19%) | 18 (17%) | 82 (20%) | 50 (19%) | 50 (19%) |
| Frequency of AECOPDs (subjects receiving placebo), n (%) | 12 | 505 | 145 | 372 | 284 | 229 |
| 0 | 5 (42%) | 152 (30%) | 47 (32%) | 110 (30%) | 86 (30%) | 69 (30%) |
| 1–2 | 6 (50%) | 232 (46%) | 65 (45%) | 173 (47%) | 131 (46%) | 105 (46%) |
| ≥3 | 1 (8%) | 121 (24%) | 33 (23%) | 89 (24%) | 67 (24%) | 55 (24%) |
Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; MBL, mannose-binding lectin.